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ABSTRACT
Objective To establish with improved accuracy the
prevalence of disease related prion protein (PrPCJD) in the
population of Britain and thereby guide a proportionate
public health response to limit the threat of healthcare
associated transmission of variant Creutzfeldt-Jakob
disease (vCJD).
Design Cross sectional opportunistic survey.
Study samples Anonymised tonsil pairs removed at
elective tonsillectomy throughout England and Scotland.
Setting National anonymous tissue archive for England
and Scotland.
Main outcome measure Presence of PrPCJD determined by
using two enzyme immunoassays based on different
analytical principles, with further investigation by
immunohistochemistry or immunoblotting of any
samples reactive in either assay.
Results Testing of 63007 samples was completed by the
end of September 2008. Of these, 12753 were from the
birth cohort in which most vCJD cases have arisen (1961-
85) and 19908 were from the 1986-95 cohort that would
have been also exposed to bovine spongiform
encephalopathy through infected meat or meat products.
None of the samples tested was unequivocally reactive in
both enzyme immunoassays. Only two samples were
reactive in one or other enzyme immunoassay and
equivocal in the other, and nine sampleswere equivocally
reactive in both enzyme immunoassays. Twohundred and
seventy six samples were initially reactive in one or other
enzyme immunoassay; the repeat reactivity rate was 15%
or less, depending on the enzyme immunoassay and cut-
off definition. None of the samples (including all the 276
initially reactive in enzyme immunoassay) that were
investigated by immunohistochemistry or
immunoblotting was positive for the presence of PrPCJD.
Conclusions The observed prevalence of PrPCJD in tonsils
from the 1961-95 combined birth cohort was 0/32661
with a 95% confidence interval of 0 to 113 per million. In
the 1961-85 cohort, the prevalence of zero with a 95%
confidence interval of 0 to 289 permillionwas lower than,
but still consistent with, a previous survey of appendix
tissue that showed a prevalence of 292 per million with a
95% confidence interval of 60 to 853 per million.
Continuing to archive and test tonsil specimens,
especially in older birth cohorts, and other
complementary large scale anonymous tissue surveys,
particularly of post-mortem tissues, will further refine the
calculated prevalence of PrPCJD.
INTRODUCTION
Although the risk to the population of Britain of dietary
exposure to the bovine spongiform encephalopathy
agent that causes variant Creutzfeldt-Jakob disease
(vCJD) has been virtually eliminated, the occurrence
to date of four cases of vCJD infection resulting from
blood transfusion has made real the threat of a second-
ary epidemic through healthcare associated human to
human transmission.1-4 These cases from blood trans-
fusion have also established the existence of an infec-
tive asymptomatic stage in human vCJD. Estimating
the prevalence of this asymptomatic infective stage,
although technically challenging, is essential to guide
a proportionate public health response to reduce the
risk of healthcare associated transmission.
Measurement of prevalence in the 1961-85 birth
cohort is a priority, given that 138 of the 167 cases of
vCJD to date in Britain have been in this group (with 39
cases in the 1961-9 and 99 in the 1970-85 birth
cohorts). Data are available from previous analyses of
appendix and tonsil specimens for the presence of dis-
ease related prion protein (designated PrPCJD) by
immunohistochemistry and immunoblotting.5 6 The
first study screened 11 247 appendix specimens and
1427 tonsil specimens by immunohistochemistry and
found three positives in the appendixes from the 1961-
85 birth cohort, giving a prevalence of 292 (95% con-
fidence interval 60 to 853) permillion.5 A second study
found no positives in 2000 tonsil specimens screened
by both immunohistochemistry and immunoblotting;6
half of these tonsils were from patients aged over
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9 years and hence in the birth cohort likely to have had
dietary exposure to bovine spongiform encephalo-
pathy. Uncertainty about the true prevalence was
increased when back calculation using plausible
assumptions from the observed clinical vCJD cases
suggested a much lower prevalence of sub-clinical
vCJD infection than would be predicted from the find-
ing of PrPCJD in three appendixes.5 7
The absence of a suitable blood test for PrPCJD, and
doubt about the clinical interpretation for a patient of a
positive test result from testing any tissue, created
major organisational and technical challenges for our
large scale prevalence survey of PrPCJD. To facilitate
semi-automated enzyme immunoassay screening, we
chose anonymised surgically removed tonsil pairs col-
lected prospectively for the study reported here, rather
than appendix tissue already archived in paraffin
blocks that would have needed more labour intensive
and slower immunohistochemical screening. PrPCJD is
known to accumulate to relatively high levels in the
tonsils of people with vCJD, although, because of the
difficulty of identifying such cases, it has not yet been
shown to be present pre-clinically.8 9
Commercially available enzyme immunoassay kits
are routinely used for testing for bovine spongiform
encephalopathy, scrapie, and other animal prion dis-
eases; however, when our survey began no validated
kits were available for testing human samples for
PrPCJD. We therefore issued a formal tender calling
for manufacturers to take part in an enzyme immuno-
assay selection study and to supply suitable kits. The
companies that responded were each sent two blinded
panels of samples. Two assays, from Microsens and
Bio-Rad, were able to detect brain from vCJD cases
diluted 10−3 and spleen diluted 10−2 into tonsil homo-
genate (Jillian Cooper, personal communication), and
we selected these for use in this study. We now report
the results of testing of the first 63 007 specimens from
the intended collection of 100 000 in a national anon-
ymous tissue archive.
METHODS
Test validation
We obtained unfixed palatine tonsil samples from 32
sheep with scrapie and 10 that were uninfected, as well
as aliquots of unfixed frozen tonsil tissue taken at
autopsy from six patients who died of vCJD. We pre-
pared 12% homogenates from these and tested them
by both enzyme immunoassays aftermaking a dilution
series from 10−1 to 10−5 with negative human tonsil
homogenate. We used a panel of 250 human tonsils
that had been previously tested and found to be nega-
tive by immunoblotting and immunohistochemistry as
examples of “true” negative controls.6
Survey tissue samples
Paired tonsil samples from people of all ages, and from
operations donebetween January 2004 andSeptember
2008, were collected from hospitals throughout Eng-
land and Scotland. One tonsil of the pair was collected
as fresh tissue chilled to 4C, and the other tonsil was
collected in formalin. Tonsils arrived at the study cen-
tre an average of 65 (mode 50, median 113) hours after
operation. Once transferred to suitable containers,
samples were stored either at −80C (fresh tissue) or at
room temperature (fixed tissue).
Patients or their carers were given a leaflet explain-
ing the aims of the study and that any result from test-
ing their tonsil could not be traced back to them. An
explicit paragraph and tick box to exercise a right to
opt out of inclusion in the survey was included in the
pre-tonsillectomy consent forms.
Investigatory algorithm
We homogenised a specimen of each tonsil pair and
screened it with both enzyme immunoassays. We
defined samples as “reactive,” “high negative,” or
“negative”by a calculation based on the optical density
readings from enzyme immunoassay for each micro-
titre plate. A reactive sample was within three standard
deviations of the cut-off, and a highnegativewaswithin
four standard deviations. We further investigated all
samples that were initially reactive in either enzyme
immunoassay or gave a high negative result in both
enzyme immunoassays by immunoblotting and
immunohistochemistry. We re-tested any sample that
was high negative in one or other enzyme immuno-
assay by both enzyme immunoassays, and if it gave a
reactive or high negative result in either we investi-
gated it further by immunoblotting and immunohisto-
chemistry. On occasion, we repeated immunoblotting
tests with the same and with alternative antibodies.
Definition of a positive result
Wedefined a tonsil positive for PrPCJD as one identified
by enzyme immunoassay that was immunohistochem-
istry positive, had the expected specific protein band
pattern in immunoblotting, or both.
RESULTS
Test performance
At a dilution of 10−3, 31 of 32 scrapie sheep samples
were reactive in both enzyme immunoassays, and at a
10−4 dilution 21were reactive in theMicrosens enzyme
immunoassay and 16 were reactive in the Bio-Rad
enzyme immunoassay. One positive sample was
detectable only at a dilution of 10−1. Dilutions of 10−2
and 10−3 could be detected by immunoblotting.
The six tonsil aliquots from human vCJD cases var-
ied in the amount of lymphoid germinal centre tissue
that was present, as judged by visual inspection.
Depending on the quality of the tissue, PrPCJD was
detectable down to a dilution of 10−3 in the Microsens
enzyme immunoassay and 10−2 in the Bio-Rad enzyme
immunoassay (table 1). The amount of PrPCJD detected
varied, as judged by the optical density values. This
variation may have been due to biological differences
in some cases, but an important contributory factorwill
have been the quality of the available tissue. Immuno-
blotting of aliquots of the vCJD samples showed that
the expected specific band patterns of PrPCJD were
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detectable. The sensitivities of the enzyme immuno-
assayswere comparable to the immunoblotting results.
Survey specimens collected
Between January 2004 and October 2008, a total of
67 696 tonsil pairs had been archived after collection
from 134 hospital trusts throughout England and Scot-
land. We received forms without tonsil tissue for 1426
patientswhoobjected and 762 inwhomclinical pathol-
ogy examination had been requested. All regions of
England contributed samples, and 5651 came from
Scotland between January 2006 and September 2008.
We also tested another 2015 anonymous specimens,
from tonsillectomies done in the southeast of England
between July 2000 and August 2002, of which half
were from patients aged over 9 years at operation,
and that were untested as part of an earlier survey.6
Enzyme immunoassay screening results
By the end of September 2008,we had screened 63 007
samples with both enzyme immunoassays and, where
indicated, completed investigatory testing (figure).
In one or other of the enzyme immunoassays, 276
samples gave an optical density defined as reactive and
638 were classed as high negative (figure). To define
the repeat reactivity rate by enzyme immunoassay,
we retested 487 reactive and high negative samples
by enzyme immunoassay at the beginning of the pro-
ject, before immunohistochemistry and immunoblot-
ting confirmatory testing. The repeat reactivity rate
was 15% (7/48) for the initially reactive samples and
3.5% (4/116) for the initially high negative samples in
theBio-Rad enzyme immunoassay.The equivalent fig-
ures for the Microsens enzyme immunoassay were
12% (7/60) and 10% (26/263). All initially reactive
samples and any initially high negative samples that
gave a repeat reactive or high negative result by
enzyme immunoassay were subject to immunohisto-
chemistry and immunoblotting confirmatory testing.
Any samples that were initially reactive or high nega-
tive butwhichwerenot repeat testedby enzyme immu-
noassay went directly for immunohistochemistry and
immunoblotting (figure).
No samples were clearly reactive in both enzyme
immunoassays. One was reactive by Microsens and
high negative by Bio-Rad, and another was reactive
by Bio-Rad and high negative by Microsens. Nine
were high negative by both the Microsens and Bio-
Rad enzyme immunoassays. Seven of these 11 samples
were methionine homozygote at codon 129 of the
prion protein gene (PRNP) and four were heterozy-
gote; only four (three homozygote and one heterozy-
gote)were frompeople born before 1996 and therefore
likely to have had dietary exposure to bovine spongi-
form encephalopathy.
Immunoblotting results
Wedemonstrated satisfactory immunoblotting perfor-
mance, using two different protocols in two separate
laboratories, by testing the tonsil tissue taken at
autopsy from vCJD patients, as well as by spiking
experiments using scrapie sheep tonsil tissue, scrapie
infected hamster brain, and human vCJD brain tissue.
None of the survey sub-sample investigated by
immunoblotting gave a protein banding pattern con-
sistent with the presence of PrPCJD. Some samples that
showed a single band, which was not consistent with
any expected pattern, were re-tested by immunoblot-
ting either with the same antibody or with different
antibodies, including 3F4 and a secondary antibody
designed to reveal non-specific antibody interactions.
Only one sample still showed a single immunoblotting
band; it wasmethionine homozygote at codon 129 and
from a patient in the 1986-90 birth cohort, and it was
negative by immunohistochemistry.
Immunohistochemistry results
More than 800 tonsils, selected on the basis of the
enzyme immunoassay results, have been investigated
Samples (n=63 007)
Bio-Rad
reactive
(n=101)
Bio-Rad
high negative
(n=160)
Dual*
EIA reactive
(n=0)
Dual* high
negative or
reactive/high
negative
(n=11)
Microsens
reactive
(n=174)
Microsens
high negative
(n=478)
Enzyme immunoassay screening of human tonsil tissue homogenates for PrPCJD *Dual enzyme
immunoassay (EIA) reactive samples gave optical density readings above the cut-off classified
as “reactive” in both Bio-Rad and Microsens tests; dual high negative or reactive/high negative
samples gave optical density readings above the cut-off classified as “high negative” in both
Bio-Rad and Microsens tests or was reactive in one and high negative in the other. All EIA
reactive samples and most high negative samples were subject to both immunoblotting and
immunohistochemistry testing (see text)
Table 1 | Enzyme immunoassay results on available tonsil tissue from six variant Creutzfeldt-
Jakob disease (vCJD) cases (including sample of brain from one case)*: highest dilutions for
reported result
Dilution†
Bio-Rad Microsens
Optical
density Interpretation
Optical
density Interpretation
Specimen 1:
Tonsil 10−2 0.06 High negative 0.12 Reactive
Brain 10−3 0.39 Reactive 0.08 Reactive
Specimen 2:
Tonsil 10−2 0.04 Negative 0.11 Reactive
Specimen 3:
Tonsil 10−2 0.06 High negative 0.20 Reactive
Specimen 4:
Tonsil 10−1 0.04 Negative 0.10 Reactive
Specimen 5:
Tonsil 10−3 0.04 Negative 0.09 Reactive
Specimen 6:
Tonsil 10−1 0.13 Reactive 0.21 Reactive
*Three specimens supplied by National CJD Surveillance Unit (including paired tonsil and brain) and three by
MRC Prion Unit.
†Dilution from 12% homogenate (100); 10−1 dilution is therefore equivalent to 0.012 g/ml vCJD tonsil tissue
homogenate; as dilution is in negative homogenate, total tissue concentration was 0.12 g/ml for all samples
tested.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 7
by immunohistochemistry in one or other of two
experienced laboratories, and none was scored posi-
tive for PrPCJD.
Prevalence estimates
Overall, 32 661 (52%) of the 63 007 samples tested
came from people born in 1995 or earlier who were
alive at the time when bovine spongiform encephalo-
pathy contaminated meat was being consumed
(table 2). The observed prevalence of PrPCJD in this
group was zero (95% confidence interval 0 to 113 per
million). Combining the 1986-90 and 1991-5 cohorts
gave a prevalence of zero with an upper 95% confi-
dence limit of 185 per million. The prevalence in the
combined 1996-2000 and 2001-7 unexposed cohorts
was also zero with an upper 95% confidence limit of
122 per million.
Although the zero permillion prevalence seen in the
1961-85 cohort (upper 95% confidence limit 289 per
million) was different from the 292 per million (95%
confidence interval 60 to 853 per million) found in
the earlier survey of appendix tissue,5 the 95% confi-
dence intervals for both surveys overlapped (a formal
comparison of the prevalence estimates gives a P value
of 0.09).
DISCUSSION
Initial results from testing the tonsil specimens in a
national anonymous tissue archive have shown the
prevalence of PrPCJD to be zero in 63 007 overall and
zero in 12 753 in the birth cohort in Britain in which
most cases of vCJD have occurred. Interpretation of
this finding, and of the difference between it and the
earlier survey of appendix tissue, depends critically
on three factors: the sensitivity of the test system cho-
sen to screen the tonsil specimens, the representative-
ness of the sample specimens of the people most
vulnerable to vCJD disease, and the natural history of
the infectivity of bovine spongiform encephalopathy
in individual patients, particularly the time when
PrPCJD first appears pre-clinically in tonsil compared
with appendix tissue and how long it persists.
Test sensitivity
Three experiments investigated the sensitivity of the
enzyme immunoassays. The first was the enzyme
immunoassay selection study, the secondwas the inter-
rogation of the enzyme immunoassays with tonsil tis-
sue from sheep with scrapie, and the third was the use
of tonsil tissue from patients who died from vCJD.
Overall, these indicated that the Microsens enzyme
immunoassay was more sensitive than the Bio-Rad
enzyme immunoassay for detection of PrPCJD in lym-
phatic tissue. The most sensitive detection was by the
Microsens enzyme immunoassay with a sample con-
taining 12 μg vCJD tonsil tissue; the equivalent for
the Bio-Rad enzyme immunoassay was 480 μg vCJD
tonsil tissue (table 1).When used for screening, 12 000
μg tonsil tissue was applied to the Microsens enzyme
immunoassay and 48 000 μg to the Bio-Rad enzyme
immunoassay. Therefore, the two enzyme immunoas-
says should have been sufficiently sensitive to detect
PrPCJD in tonsils from asymptomatic people incubating
vCJD if levels of PrPCJDwere a 10th to a 1000th of those
in patients with symptoms.
The dual enzyme immunoassay tonsil screening
protocol may be at least as sensitive as any other
large scale testing for abnormal prion protein that
could have been used. The enzyme immunoassays
use different test principles and antibodies, perhaps
reinforcing the sensitivity of each. Reading of the
results was automated, and we used a range of controls
on each 96 well plate of tests. We deemed the use of a
single enzyme immunoassay cut-off value as com-
monly applied to screen a population with many posi-
tives to be inappropriate, as this particular set of
samples was expected (and found) to be overwhel-
mingly negative. Therefore, we calculated the cut-off
value for each plate individually, and this method
almost doubled the number of specimens that were
selected for further investigation by immunoblotting
and immunohistochemistry.
Several reasons exist why a specimen could have
given a false high (reactive or high negative) optical
density reading in either or both enzyme immuno-
assays: inadequate proteinase K digestion of PrPC (the
normal cellular form of PrP) for the Bio-Rad enzyme
immunoassay, inadequate removal of PrPC bound to
the capture polyanion for the Microsens enzyme
immunoassay, non-specific antibody interactions
owing to the high antibody concentration in tonsil tis-
sue, and poor sample quality or technical failures.
Therefore, applying more specific immunoblotting
and immunohistochemistry tests to confirm whether
PrPCJD was present was essential.
In comparison with immunohistochemistry, the
volume of tonsil tissue screened by enzyme immuno-
assay was relatively large. Immunohistochemistry on
appendix tissuemay also be less specific than immuno-
blotting, so that prevalence estimated by immunohis-
tochemistry screening may tend to overestimate the
true situation.9 However, to tackle the lingering uncer-
tainty that screening immunohistochemistry might be
more sensitive than dual enzyme immunoassay
Table 2 | Prevalence of disease related prion protein (PrPCJD) in Britain by birth cohort
(positive/total; rate per million with 95% confidence intervals*)
Birth cohort
Current (2004-September 2008)
national tissue survey: tonsils
Earlier† (1995-9) national tissue survey
Appendices Tonsils
1940 and before NA NA 0/225
1941-60 NA 0/573 0/266
1961-85 0/12 753; 0 (0 to 289) 3/10278;292(60to853) 0/694
1986-90 0/9 564; 0 (0 to 386) 0/396 0/119
1991-5 0/10 344; 0 (0 to 357) NA 0/106
1996-2000 0/15 708; 0 (0 to 253) NA 0/17
2001-7 0/14 638; 0 (0 to 252) NA NA
Total 0/63 007; 0 (0 to 59) 3/11247;267(55to779) 0/1 427; 0 (0 to 2
582)
NA=not available.
*95% confidence interval calculated only when denominator exceeds 1000.
†Data from separate tissue survey of 2000 tonsils (July 2000-August 2002) in southeast England (including
London)6 not included.
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screening, a further study to re-test 10 000 of the
archived tonsils by immunohistochemistry has been
commissioned. These 10 000 samples comprise those
frompatients in the 1961-85 birth cohort, as well as any
samples that gave optical density readings above the
cut-offs in either of the two enzyme immunoassays.
The results from this major undertaking should be
available some time during 2009.
Two of the three positive samples in the retrospec-
tive immunohistochemistry study of appendix tissue
were valine homozygous at codon 129 of PRNP.5 10
Therefore, we can be confident that the antibodies
used in our immunohistochemistry analysis would
have showed PrPCJD in a valine homozygote if it was
present. The antibodies used in the enzyme immuno-
assay and immunoblotting would similarly be likely to
detect PrPCJD in a valine homozygote and, by exten-
sion, PrPCJD in a heterozygote. Although the immuno-
blotting profiles of valine homozygote and
heterozygote vCJD are unknown, they may be
expected to consist of three or four glycoforms.11 The
immunoblotting profile of the spleen in a case of
asymptomatic vCJD infection in a heterozygote
patient showed similarities to that in clinical vCJD
spleen samples in methionine homozygote patients,
with a predominance of the diglycosylated band.2 We
did not observe by immunoblotting anypattern similar
to any recognised profiles in sporadic CJD or
vCJD.12-16 The only repeatedly anomalous immuno-
blotting pattern seen was of a single immunoblotting
band in an immunohistochemistry negative sample,
which was methionine homozygote at codon 129 of
PRNP.
Representativeness of sample
The age and sex characteristics of the samples in our
study reflected the current age and sex distribution of
people having tonsillectomy: 72% of those born in
1995 or earlier in our survey were female, compared
with 48%of those born since 1995. Although only 44%
of vCJD cases to date have been in women, we do not
think that the predominance of females in our older
sample of tonsils could have biased our findings with
respect to prevalence of PrPCJD.
Given the very strong association between PrPCJD
and people who are homozygous for methionine at
PRNP codon 129,5 it is important to note that our sam-
ple was likely to have been representative of this
genetic susceptibility: an analysis of 466 of the tonsils
in our survey showed 47% to be methionine homozy-
gotes at codon 129, consistent with what was
expected.10 17-20 Therefore, of the 32 661 tonsils tested
from people born before 1996, approximately 15 351
(47%) would have been from methionine homozy-
gotes.
Several differences must be considered when com-
paring results between surveys. First and foremost is
that previously appendix tissues were screened by
immunohistochemistry, whereas we screened tonsil
tissue by enzyme immunoassay. Secondly, an average
of 10 years elapsed between when the previous large
sample from the 1961-85 birth cohort had their appen-
dixes removed (during 1995-9) until our sample had
their tonsils removed (mostly in 2006-7)—10 years
during which abnormal prion protein levels might be
expected to have increased rather than diminished.
Within this birth cohort, however, the average age of
appendicectomy was estimated to be four years older
than the average age of tonsillectomy, so the average
duration of the opportunity for PrPCJD to increase
between the appendicectomy samples and the tonsil-
lectomy samples would have been about six years. On
the other hand, the relatively older appendix sample
that was collected earlier may conceivably have con-
tained a wave of infectivity in the 1961-85 cohort of the
British population that was not present in the younger
tonsil group that was sampled later.
Detailed information on previous operative history
was sought on every vCJD case diagnosed in Britain.
Seventeen of 167 patients were reported to have had
tonsillectomy; 14 of these were in the 1961-85 birth
cohort, and the remaining three were in the pre-1960
birth cohort. None was likely to have had specimens
included in this or the earlier tonsil survey (Hester
Ward, personal communication).6
Natural history
While PrPCJD has been found consistently by immuno-
blotting and immunohistochemistry in tonsil tissue
from patients with vCJD,89 21-24 PrPCJD in a tonsil from
an asymptomatic person has yet to be reported. Given,
however, that tonsillar tissue has been shown to accu-
mulate PrPSc before the onset of clinical disease in non-
human primates and well before the onset of clinical
disease in sheep experimentally infected orally with
bovine spongiformencephalopathy,25 26we considered
tonsil tissue to be a reliable substrate for a survey of
prevalence in humans. Also, the use of fresh tonsil tis-
sue allowedmore comprehensive laboratory testing, if
necessary, after the initial screening assays.
PrPCJD has been observed to accumulate in appendix
tissue in vCJD (19/20 positive/tested)927 28 and, in two
cases, before symptoms developed.29 30 However, data
on the timing of the appearance of PrPCJD in different
peripheral lymphoreticular tissues during the pro-
longed incubation period of vCJD are sparse. The
rate of accumulation of PrPCJD in tonsil and appendix
tissue could differ such that the findings of surveys of
appendix and tonsil tissues would also differ. The posi-
tive samples found in the appendix survey presumably
came from people who were infected a relatively short
time earlier, during the peak of the bovine spongiform
encephalopathy epidemic.5 Moreover, should the
incubation period for prion disease be considerably
longer in people with different genotypes, uncertainty
about the timing of the appearance of detectable PrPCJD
in these will increase, with concomitant implications
for the interpretation of results of PrPCJD prevalence
surveys.
Animal experiments have shown that high infectiv-
ity, and indeeddisease, can be present in the absence of
detectable proteinase K resistant PrPSc.31 The extent to
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which this observation can be generalised is, however,
unclear, as PrPCJD has been shown to be present in the
lymphoid tissues of all vCJDpatients tested.9 27 If other,
more reliable, indicators of vCJD become available,
screening the existing samples with tests for these mar-
kers, and thereby determiningwhether any vCJDposi-
tives have beenmissed by looking only for PrPCJD,may
be possible.
Data from animal experiments also show “clear-
ance” of abnormal prion protein after inoculation.31 32
Therefore, the abnormal prion protein found in the
earlier survey of appendix tissue may conceivably
have been transient and eventually cleared without
leading to disease, so that the appendix survey result
would not have been replicated by the later tonsil sur-
vey.
Conclusion
We tested more than 32 000 tonsils from people in the
age range most exposed to meat contaminated with
bovine spongiform encephalopathy, and believed to
be asymptomatic when sampled, for disease related
prion protein. Using two sensitive enzyme immunoas-
says,with selective applicationof specific immunoblot-
ting and immunohistochemistry techniques, we found
no samples positive for PrPCJD, a prevalence of 0 per
million (with an upper 95% confidence limit of 113 per
million). For the 1961-85 birth cohort, the prevalence
of zero with a 95% confidence interval of 0 to 289 per
million was lower than, but still consistent with, the
earlier study of appendix tissue (60 to 853 permillion).
A P value of 0.09 applies to the comparison of the two
prevalence estimates. These two surveys may not,
however, be directly comparable owing to differences
in testing methods, tissues sampled, and the time the
tissues were removed (typically about 10 years earlier
in the previous study). More data are needed through
continuing the testing of tonsils from people born
before 1996, despite the low frequency of tonsillect-
omy in older birth cohorts. In addition, creation and
testing of other anonymous tissue archives, such as one
based on coronial autopsies, or a repeat of the appen-
dix survey on an even larger scale, should provide a
larger sample set of the people most exposed to the
bovine spongiform encephalopathy agent.33
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